Overview
Compare with Autolus Therapeutics, Cellectis or Compugen Ltd., or pick any stock.
- TickerRXRX on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersSalt Lake City1
- Websitewww.recursion.com
- Incorporated inDE5
- Business address41S Rio Grande Street, Salt Lake City, Ut 841015
- Filer categoryLarge accelerated filer5
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-867.9%Operating margin4
-863.4%Net margin4
26.9%Revenue growth, 20254
-57.0%Return on equity4
-$378.3MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License and Service brought in 99% of the revenue Recursion Pharmaceuticals broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| License and Service | $43.9M | $58.5M | $74.3M |
| Grant | $699.0K | $351.0K | $425.0K |
Regions
United States brought in 53% of the revenue Recursion Pharmaceuticals broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $43.8M | $57.4M | $39.3M |
| United Kingdom | $0 | $1.1M | $35.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue13¢$71.0M
- Research and development87¢$475.3M
- Income tax0¢$136.0K
Out of $74.7M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $74.7M | $58.8M | $44.6M |
| Cost of revenue | $71.0M | $45.2M | $42.6M |
| Research and development | $475.3M | $314.4M | $241.2M |
| General and administrative | $176.6M | $178.2M | $110.8M |
| Total operating costs and expenses | $722.8M | $537.8M | $394.6M |
| Loss from operations | -$648.1M | -$479.0M | -$350.1M |
| Other income, net | $3.2M | $14.2M | $17.9M |
| Loss before income tax benefit | -$644.9M | -$464.8M | -$332.1M |
| Income tax benefit | $136.0K | $1.1M | $4.1M |
| Net loss | -$644.8M | -$463.7M | -$328.1M |
| Net loss per share of class A, B and exchangeable common stock, basic (in dollars per share) | -$1.44 | -$1.69 | -$1.58 |
| Net loss per share of class A, B and exchangeable common stock, diluted (in dollars per share) | -$1.44 | -$1.69 | -$1.58 |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares) | 447.4M shares | 274.2M shares | 207.9M shares |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares) | 447.4M shares | 274.2M shares | 207.9M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $743.3M | $594.4M | |
| Restricted cash | $4.6M | $3.0M | |
| Other receivables | $24.6M | $49.2M | |
| Prepaid data assets | $11.7M | $29.6M | |
| Other current assets | $28.6M | $38.1M | |
| Total current assets | $812.8M | $714.3M | |
| Restricted cash, non-current | $6.0M | $5.6M | |
| Property and equipment, net | $103.9M | $141.1M | |
| Operating lease right-of-use assets | $45.3M | $65.9M | |
| Financing lease right-of-use assets | $20.2M | $26.3M | |
| Intangible assets, net | $309.9M | $335.9M | |
| Goodwill | $162.2M | $148.9M | $52.1M |
| Deferred tax assets | $957.0K | $1.9M | |
| Other assets, non-current | $12.8M | $8.8M | |
| Total assets | $1.5B | $1.4B | |
| Accounts payable | $18.1M | $21.6M | |
| Accrued expenses and other liabilities | $70.2M | $81.9M | |
| Unearned revenue | $37.6M | $61.8M | |
| Operating lease liabilities | $12.7M | $13.8M | |
| Notes payable and financing lease liabilities | $9.1M | $8.4M | |
| Total current liabilities | $147.7M | $187.5M | |
| Unearned revenue, non-current | $114.0M | $118.8M | |
| Operating lease liabilities, non-current | $46.6M | $67.2M | |
| Notes payable and financing lease liabilities, non-current | $9.6M | $19.0M | |
| Deferred tax liabilities | $23.3M | $16.6M | |
| Other liabilities, non-current | $2.1M | $4.7M | |
| Total liabilities | $343.3M | $413.8M | |
| Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2025 and December 31, 2024; 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) and 396,802,394 (Class A 389,547,223 and Class B 6,958,575 and Exchangeable 296,596) issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $5.0K | $4.0K | |
| Additional paid-in capital | $3.2B | $2.5B | |
| Accumulated deficit | -$2.1B | -$1.4B | |
| Accumulated other comprehensive income (loss) | $36.7M | -$7.6M | |
| Total stockholders equity | $1.1B | $1.0B | $463.4M |
| Total liabilities and stockholders equity | $1.5B | $1.4B | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 2.0B shares | 2.0B shares | |
| Common stock, shares issued (in shares) | 528.2M shares | 396.8M shares | |
| Common sock, shares outstanding (in shares) | 528.2M shares | 396.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$644.8M | -$463.7M | -$328.1M |
| Depreciation and amortization | $83.7M | $36.5M | $24.4M |
| Stock-based compensation | $111.2M | $81.7M | $53.5M |
| Asset impairment | $6.0M | $108.0K | $1.2M |
| Lease expense | $22.2M | $16.6M | $8.1M |
| Loss on disposal of a business | $4.5M | $0 | $0 |
| Acquired IPR&D | $22.1M | $0 | $0 |
| Other, net | $9.6M | $16.3M | -$2.6M |
| Other receivables and assets | $32.9M | -$6.1M | -$7.8M |
| Prepaid data assets | $49.9M | -$8.8M | $6.0M |
| Unearned revenue | -$36.8M | -$28.0M | -$41.1M |
| Accounts payable | -$2.6M | $6.4M | -$987.0K |
| Accrued development expense | -$2.3M | -$264.0K | $2.7M |
| Accrued expenses and other current liabilities | -$7.4M | $5.5M | $6.7M |
| Lease liabilities | -$20.0M | -$15.6M | -$9.9M |
| Net cash used in operating activities | -$371.8M | -$359.2M | -$287.8M |
| Net cash acquired in the acquisition of a business | $0 | $277.1M | $1.8M |
| Purchases of property and equipment | -$6.5M | -$13.7M | -$12.0M |
| Purchases of intangible assets | -$2.2M | -$3.4M | -$597.0K |
| Decrease in cash related to disposal of a business | -$4.4M | $0 | $0 |
| Purchases of investments | -$3.8M | $0 | $0 |
| Sales and maturities of investments | $0 | $0 | $480.0K |
| Net cash provided by (used in) investing activities | -$16.9M | $260.1M | -$10.2M |
| Proceeds from issuance of common shares, net of issuance costs | $528.9M | $300.4M | $128.1M |
| Proceeds from equity incentive plans | $4.1M | $8.1M | $12.8M |
| Repayment of long-term debt and finance lease liabilities | -$8.4M | -$4.4M | -$766.0K |
| Purchase of an intangible asset | -$3.0M | $0 | $0 |
| Net cash provided by financing activities | $521.5M | $304.1M | $140.1M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $18.0M | -$3.4M | $188.0K |
| Net change in cash, cash equivalents and restricted cash | $150.9M | $201.6M | -$157.7M |
| Issuance of shares for the acquisitions of businesses and agreement | $20.3M | $630.1M | $89.3M |
| Accrued property and equipment | $0 | $439.0K | $2.4M |
| Purchase of an intangible asset | $0 | $6.0M | $0 |
Former names
- Recursion Pharmaceuticals, LLCApr 2, 2014 to Dec 4, 20155
Timeline
- 2013Founded Founded1
Recent filings
- Oct 7, 20264
- Oct 7, 20264
- Oct 6, 2026144
- Oct 6, 2026144
- Oct 2, 20264
- Oct 2, 20264
- Sep 21, 20268-K
- Sep 16, 20264
- Sep 10, 20264
- Sep 8, 2026144
- Sep 2, 20264
- Sep 1, 2026144
- Aug 21, 2026144
- Aug 20, 2026144
- Aug 19, 2026144
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.recursion.com1
- X (Twitter)x.com/recursionpharma1
- LinkedInwww.linkedin.com/company/recursion-pharmaceuticals1
- WikidataQ120877642
- SEC EDGARCIK 1601830
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteRecursion Pharmaceuticals logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12